New antibiotic can help treat drug-resistant pathogens

Researchers from Johns Hopkins University and Medicine have designed a potential new antibiotic for a pathogen that is highly resistant to drugs and is often lethal to individuals suffering from lung diseases, including cystic fibrosis.

Called Mycobacterium abscessus, the pathogen is associated with a commonly known bacterium that causes leprosy and tuberculosis but has lately evolved as a distinct species that often manifests as a virulent lung infection.

The researchers from the Department of Chemistry at Krieger School of Arts & Sciences and the infectious diseases department of the School of Medicine have published their results in the Communications Biology journal.

The researchers have designed one of the first promising treatments of a microbe that has a cure rate of less than 50% and no FDA-approved treatments. Before the compound, known as T405, can become a viable clinical treatment, investigators should enhance its pharmacological potency through a preclinical animal infection model.

People die of this in our hospitals every week. The data we have is very promising.”

Craig Townsend, Professor of Chemistry, Johns Hopkins University

Professor Townsend has also worked as a principal investigator on the study together with an associate professor of medicine, Gyanu Lamichhane.

In spite of years of urgent calls for additional studies to interpret the bacteria and to seek potential treatments, scientists have been cautious of testing the most harmful member of its Non-Tuberculosis Mycobacteria (NTM) family.

It’s still considered an emerging disease. There are now more NTM than tuberculosis cases in the United States. And this is the most virulent of all of them.”

Gyanu Lamichhane, Associate Professor of Medicine, Johns Hopkins University

According to the article, the T405 compound has shown a “superior potency against M. abscessus” over two widely used antibiotics. When paired with a current drug, known as avibactam, the T405 compound was also able to inhibit the bacteria from developing resistance.

Furthermore, the T405 compound was well tolerated in mice and can possibly be administered less than present-day treatments. This approach will expose patients to fewer toxic side effects, like deafness.

Individuals with lung diseases and depressed immune systems also face a risk of contracting an infection that is often seen in patients with cystic fibrosis. Transmission is yet to be fully interpreted, but the microorganisms can be detected in water, dust, and soil. It induces infections in the lungs, skin, and soft tissues.

According to the article, present therapeutic guidelines for the infection need 12 to 18 months of multidrug treatment and this has resulted in cure rates between 30% and 50%, highlighting the “need for new antibiotics with improved activity”.

Journal reference:

Batchelder, H. R., et al. (2020) Development of a penem antibiotic against Mycobacteroides abscessus. Communications Biology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Azthena logo powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists Reinvent Spectinomycin as a Powerhouse Weapon for Drug-Resistant Superbug